Late Stage Chronic Kidney Disease Drugs Market 2027 Top Players- AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd

According to our new market research study titled” Late Stage Chronic Kidney Disease Drugs Market - Global Analysis and Forecast by Product Type, Indication and Distribution Channel” the global late stage chronic kidney disease drugs market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% from 2020 to 2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.
Request Sample Copy Of this Report @ https://bit.ly/3maAExt

Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Factors such as high prevalence of hyperparathyroidism, increased research studies on calcimimetics are some of the impacting factors which drive the segment growth. For instance, in February 2017, Amgen received the US Food and Drug Administration (FDA) approval for Parsabiv, an etelcalcetide, for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that is used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.

The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
By Product Type
• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders
By Indication
• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Purchase Copy of this Report @ https://bit.ly/3a4oCDt
Based on indication, the late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. End-stage renal disease (ESRD) patients are at high risk for hyperkalemia, especially when other factors and comorbidities that interfere with renal potassium excretion are present. The prevalence of hyperkalemia in CKD patients is considerably higher than in the general population. Chronic hyperkalemia is a major concern in ESRD patients, especially for those who administer RAAS blockades for cardiac disease and/or diabetes. Potassium binding agents are useful in maintaining the serum potassium in the normal range without lowering the dose or discontinuing RAAS inhibitors and restricting the intake of vegetables and fruits.

Contact:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

This release was published on openPR.